@article {Leung1802460, author = {Janice M. Leung and Ma{\textquoteright}en Obeidat and Mohsen Sadatsafavi and Don D. Sin}, title = {Introduction to Precision Medicine in COPD}, elocation-id = {1802460}, year = {2019}, doi = {10.1183/13993003.02460-2018}, publisher = {European Respiratory Society}, abstract = {Although there has been a tremendous growth in our understanding of chronic obstructive pulmonary disease (COPD) and its pathophysiology over the past several decades, the pace of therapeutic innovation has been extremely slow. COPD is now widely accepted as a heterogeneous condition with multiple phenotypes and endotypes. Thus, there is a pressing need for COPD care to move from the current {\textquotedblleft}one-size-fits-all{\textquotedblright} approach to precision medicine that takes into account individual variability in genes, environment, and lifestyle for each patient. Precision medicine is enabled by biomarkers that can accurately identify subgroups of patients who will most likely to benefit from therapeutics and those who will only experience harm (predictive biomarkers); predict therapeutic responses to drugs at an individual level (response biomarkers) and segregate patients who are at risk of poor outcomes from those who have relatively stable disease (prognostic biomarkers). In this essay, we will discuss the current concept of precision medicine and its relevance for COPD and explore ways to implement precision medicine for millions of patients across the world with COPD.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Leung has nothing to disclose.Conflict of interest: Dr. OBEIDAT has nothing to disclose.Conflict of interest: Dr. Sadatsafavi has nothing to disclose.Conflict of interest: Dr. Sin reports grants from AstraZeneca, during the conduct of the study; grants from Merck, personal fees from Sanofi-Aventis, personal fees from Regeneron, grants and personal fees from Boehringer Ingelheim, grants and personal fees from AstraZeneca, personal fees from Novartis, outside the submitted work.}, issn = {0903-1936}, URL = {https://erj.ersjournals.com/content/early/2019/01/16/13993003.02460-2018}, eprint = {https://erj.ersjournals.com/content/early/2019/01/16/13993003.02460-2018.full.pdf}, journal = {European Respiratory Journal} }